Evommune, Inc. filed a current report on September 15, 2026, disclosing that the Delaware-incorporated biopharmaceutical company published an updated corporate presentation on its investor relations website under Regulation FD.

Key Highlights

  • Regulation FD disclosure: Evommune posted an updated corporate presentation on September 15, 2026, furnished as Exhibit 99.1 to the current report.
  • Exchange listing: Evommune common stock, $0.0001 par value per share, trades on NYSE under the symbol EVMN (NYSE:EVMN).
  • Emerging growth company: Evommune is classified as an emerging growth company and has not elected to opt out of the extended transition period for new accounting standards.
  • Signed by CEO: The report was signed by Luis Pena, President and Chief Executive Officer, on September 15, 2026.
  • No filing liability: According to the filing, the furnished information "shall not be deemed 'filed' for the purposes of Section 18 of the Securities Exchange Act of 1934."

Evommune Furnishes Corporate Presentation Under Regulation FD

Evommune, Inc., a Delaware-incorporated company headquartered at 1891 Page Mill Road, Palo Alto, California 94304, disclosed on September 15, 2026 that it had posted an updated corporate presentation to the investor relations section of its website. The presentation was simultaneously furnished to the SEC as Exhibit 99.1 to the current report, in compliance with Regulation FD disclosure requirements under Item 7.01.

According to the filing, the company explicitly stated that its website and any information contained on it "are not incorporated by reference into this Current Report." The company also noted it "undertakes no obligation to update, supplement or amend the materials attached hereto as Exhibit 99.1." The filing identifies Evommune as an emerging growth company under Rule 405 of the Securities Act of 1933 and Rule 12b-2 of the Securities Exchange Act of 1934, with Commission File Number 001-42938 and IRS Employer Identification Number 85-0742575.

The current report includes two exhibits: Exhibit 99.1, described as the "Evommune, Inc. Presentation, dated September 15, 2026," and Exhibit 104, a Cover Page Interactive Data File embedded within an Inline XBRL document. The report was executed by Luis Pena, who serves as President and Chief Executive Officer of the company, as the duly authorized signatory on behalf of Evommune.

What Was Disclosed

Evommune, Inc. (NYSE:EVMN) furnished an updated corporate presentation dated September 15, 2026 under Regulation FD. The presentation is attached as Exhibit 99.1 and is not deemed "filed" for liability purposes under Section 18 of the Exchange Act, according to the filing.